Memantine Ratiopharm (Memantine Hydrochloride)

Memantine Hydrochloride acts as a non‑competitive antagonist of the NMDA‑type glutamate receptor. By blocking the receptor‑associated ion channel, it reduces excessive calcium entry into neurons during pathological glutamate activation, thereby decreasing excitotoxic damage and providing neuroprotective effects.

The specific dose of Memantine Ratiopharm is determined by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Physicians typically start with a low dose and titrate upward, but exact dosing regimens should only be provided by a qualified healthcare professional.

The safety of Memantine Hydrochloride in pregnancy and lactation has not been established, and the pregnancy category is listed as unknown. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their physician before use.

To order Memantine Ratiopharm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas the most common alternative for Alzheimer’s disease is the acetylcholinesterase inhibitor class (e.g., donepezil). Memantine targets glutamate‑mediated excitotoxicity, while acetylcholinesterase inhibitors enhance cholinergic transmission. Clinical practice often uses them together for complementary mechanisms.

Memantine Ratiopharm tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Memantine Ratiopharm is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, according to the prescribing physician’s instructions.

Serious risks include the potential for seizures, severe allergic reactions such as anaphylaxis, and hepatic injury indicated by abnormal liver function tests. Patients should be monitored for any new neurological symptoms, rash, or signs of liver dysfunction and seek medical attention promptly if they occur.

Memantine should not be used by individuals with known hypersensitivity to memantine or any of its excipients. It is also contraindicated in patients with severe renal impairment unless dose‑adjusted, and it should be avoided in combination with other NMDA antagonists due to the risk of excessive CNS depression.